Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Amphastar Pharmaceuticals
AMPH
Amphastar Pharmaceuticals
Intensifying Pricing Pressure Will Erode Margins And Revenue
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
07 May 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$25.00
19.3% overvalued
intrinsic discount
20 Aug
US$29.83
1Y
-38.0%
7D
0.2%
Loading
1Y
-38.0%
7D
0.2%
Author's Valuation
US$25.0
19.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$25.0
19.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-13m
772m
2014
2017
2020
2023
2025
2026
2028
Revenue US$772.3m
Earnings US$140.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.96%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$140.35m
Earnings '28
x
9.11x
PE Ratio '28
=
US$1.28b
Market Cap '28
US$1.28b
Market Cap '28
/
42.04m
No. shares '28
=
US$30.40
Share Price '28
US$30.40
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$24.97
Fair Value '25
